MedReleaf Announces Involvement in Cancer Clinical Trial

MedReleaf (TSX:LEAF) announced a partnership with the Ontario Clinical Oncology Group (OCOG) for a cancer trial to investigate the management of cancer pain with cannabis oil.

As quoted in the press release:

The OCOG directed by Dr. Mark Levine will coordinate the trial. Dr. Marissa Slaven, a specialist in pain management and palliative care is the Principal Investigator. The study will be conducted at the HHS Juravinski Cancer Centre in Hamiltonover a one-two year period. Patients with cancer related pain will be administered MedReleaf’s uniquely formatted cannabis oil capsules with the objective of improving pain management.

Cancer patients experiencing pain despite other pain medications may be eligible to participate. The aim of the trial is to assess the effect of cannabis oil in relieving their symptoms and to gain information on the best oral dosing regimen. Patients will receive an oil combining THC and CBD.

“Patients with cancer often suffer from significant pain and we know that while managing the pain with narcotics is often necessary, it is also fraught with issues,” said Dr. Marissa Slaven. “Anecdotally, cancer patients have been telling us that cannabis products help their pain. Thanks to MedReleaf’s commitment to advancing medical science we will now be able to start gathering the data needed to help our patients live better.”

Click here to read the full press release.